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Glycemic control and use of 
glucose-lowering medications in 
hospital-admitted type 2 diabetes 
patients over 80 years
Ditte Resendal Gotfredsen1, Siri Vinther1, tonny Studsgaard petersen1,2, Rikke cortes1, 
thomas Bo Jensen  1,2, espen Jimenez-Solem1,2 & Mikkel Bring christensen1,2,3*
Treatment guidelines for type 2 diabetes (T2D) recommend avoidance of hypoglycemia and less 
stringent glycemic control in older patients. We examined the relation of glycemic control to glucose-
lowering medications use in a cohort of patients aged>80 years with a diagnosis of T2D and a hospital 
admission in the Capital Region of Denmark in 2012–2016. We extracted data on medication use, 
diagnoses, and biochemistry from the hospitals’ records. We identified 5,172 T2D patients with high 
degree of co-morbidity and where 17% had an HbA1c in the range recommended for frail, comorbid, 
older patients with type 2 diabetes (58–75 mmol/mol (7.5–9%)). Half of the patients (n = 2,575) had an 
HbA1c <48 mmol/mol (<6.5%), and a majority of these (36% of all patients) did not meet the diagnostic 
criteria for T2D. Of patients treated with one or more glucose-lowering medications (n = 1,758), 
20% had HbA1c-values <42 mmol/mol (<6%), and 1% had critically low Hba1c values <30 mmol/mol 
(<4.9%), In conclusion, among these hospitalized T2D patients, few had an HbA1c within the generally 
recommended glycemic targets. One third of patients did not meet the diagnostic criteria for T2D, 
and of the patients who were treated with glucose-lowering medications, one-fifth had HbA1c-values 
suggesting overtreatment.
For patients with type 2 diabetes, it is important to maintain blood glucose levels as close to normal as possible 
in order to reduce the risk of micro- and macrovascular complications1–4. Treatment should, however, be indi-
vidualized according to comorbidities, disease duration, risk of adverse events and in particular hypoglycemia, 
life expectancy as well as the patient’s own preferences, resources and support system1. Elderly people with type 2 
diabetes will generally have co-existing illness and relatively few resources5. Life expectancy will often be shorter 
than the time it takes for micro- and macrovascular disease complications to develop and manifest6,7. This is in 
contrast to the potential adverse effects of glucose-lowering medications that often appear in the short term. 
Hypoglycemia is the most important example of an acute and potentially fatal adverse effect to which elderly 
are particularly vulnerable8–15. Less effective counterregulatory mechanisms, decreased drug elimination, motor 
and cognitive impairment as well as unspecific/uncharacteristic symptoms all contribute to the heightened risk 
in elderly patients16. Thus, the overall goal with treatment individualization should be to weigh the typically 
long-term benefits vs. therapy burden and risk of adverse events on the shorter term7,15,17,18. Available evidence 
from the few clinical trials enrolling elderly patients with type 2 diabetes support that the benefits of intensive 
glycemic control targeting near-normal glycemia may not outweigh potential risks in this population8,19–22. This 
is also reflected in several international guidelines which generally advocate a less stringent treatment approach 
for older people with coexisting illnesses. An HbA1c target of 58–75 mmol/mol (7.5–9%) after pharmacological 
intervention, is generally recommended1,6,7,17. Recent studies have, however, questioned the extent to which these 
recommendations have been adopted and implemented in clinical practice12,23,24.
Previous studies examining trends in use, effects (glycemic control as measured by HbA1c) and harms (e.g. 
hypoglycemia) of glucose-lowering medications have predominantly focused on the general type 2 diabetes pop-
ulation25–31. This study focuses on a cohort of patients aged 80 years or older with a diagnosis of type 2 diabetes 
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and a hospital-based health record in the period 2012–2016. The main objective was to examine glycemic con-
trol in relation to use of glucose-lowering medications; secondary objectives included characterizing the patient 
cohort with regards to comorbidity, drug administration and biochemical status at the time of hospital admission.
Results
patient characteristics and admission diagnoses. A total of 5,172 patients with type 2 diabetes were 
included in the study (Table 1). The median age was 84 years (IQR 82–88 years) and 54% of the patients were 
female. Based on Body Mass Index (BMI), 41% were normal weight (BMI 18.5–25 kg/m2) and 55% were over-
weight or obese (BMI >25 kg/m2) (Table 1). Regarding biochemical status, LDL-cholesterol was >2,5 mmol/L 
for 25% of the patients. The estimated glomerular filtration rate (eGFR) was ≤60 mmol/L for 57% of the patients 
and 56% had a hemoglobin below the reference level calculated for men and women respectively (Table 1). The 
median duration of hospital admission was four days with pneumonia being the most common cause of admis-
sion (4%, n = 211). Diabetes related diagnoses were registered as the primary cause of admission for 2% (n = 78) 
of all patients and 1% (n = 70) had hypoglycemia as the primary cause of admission.
Comorbidities. The majority (82%, n = 4,228) of patients had a high level of comorbidity with a value >2 on 
the Charlson Comorbidity Index (Table 1). Detailed data on the cognitive status of the patients was not available, 
but 16% had a diagnosis of dementia (Table 2). Hypertension was the most commonly registered comorbidity 
(71%), followed by congestive heart failure (32%), peripheral vascular disease (18%) and previous myocardial 
infarction (13%) (Table 2).
Glycemic control. The distribution of HbA1c values is shown in Fig. 1. Most patients (91%, n = 4,710) had an 
HbA1c between 30–75 mmol/mol (4.9–9%). Half of the patients (n = 2,575) had an HbA1c <48 mmol/mol (<6.5%), 
and 26% (n = 1,361) had an HbA1c <42 mmol/mol (<6%). In the other end of the spectrum, 8% (n = 405) had 
HbA1c-values >75 mmol/mol (>9%) (Table 1). A total of 17% (n = 891) had an HbA1c between 58–75 mmol/mol 
(7.5–9%), i.e. within the interval recommended for elderly, comorbid patients with overt type 2 diabetes (Table 1).
Glucose-lowering medications. Close to one third of patients (34%, n = 1,758) were treated with at 
least one glucose-lowering medication at discharge (Table 3); 41% (n = 2,100) were administered at least one 
glucose-lowering medication, including sliding scale bolus insulin, during the index hospital admission (data 
not shown). Among the patients treated with glucose-lowering medication at discharge, one fourth (25%, 
n = 448) were treated with two or more glucose-lowering medications (Table 3). The most commonly used 
glucose-lowering medications were metformin (50%), basal insulin (32%), bolus insulin (10%), sulphonylureas 
(14%) and dipeptidyl peptidase-4 inhibitors (14%) (Table 4).
Glucose-lowering medications in relation to glycemic control. Of those treated with a 
glucose-lowering medication at discharge (n = 1,758), close to half 48%, n = 844) had an HbA1c within the 
interval recommended for elderly without significant comorbidity (43–57 mmol/mol (6.0–7.5%)). One third had 
higher HbA1c-values, 21% (n = 374) had a Hba1c between 58–74 mmol/mol (7.5–9), and 10% (n = 182) had 
Hba1c >75 mmol/mol (9%); while the remaining 20% (n = 343) had near-normalized Hba1c (<42 mmol/mol 
(6%)) while continuing glucose-lowering medication at discharge. Of the patients with near-normalization 
of Hba1c values, 15% (n = 52) took two or more glucose-lowering medications (Table 3, Fig. 1) most fre-
quently metformin, insulin and sulphonylureas (Table 4). One percent (n = 15) of the patients treated with an 
glucose-lowering medication at discharge had very low Hba1c-values <30 mmol/mol (<4.9%) (Table 3, Fig. 1).
For those patients who did not receive a glucose-lowering medication at discharge (n = 3,414), 55% (n = 
1,865) had HbA1c-values that did not justify a diagnosis of type 2 diabetes (i.e. HbA1c <48 mmol/mol (<6,5%)) 
(Table 3, Fig. 1). At the other end of the spectrum, 7% (n = 223) had Hba1c levels for which glucose-lowering 
medications are generally recommended (i.e.>75 mmol/mol (9%)).
Discussion
Based on hospital electronic health records covering the entire population of the Capital Region of Denmark (1.8 
million inhabitants) from 2012 to 2016, we investigated the demographics and the degree of glycemic control 
in relation to glucose-lowering medications in patients with type 2 diabetes aged 80 years or more. Our main 
findings were (1) almost half of the patients had an HbA1c<48 mmol/mol (<6,5%), and of these 72% (n = 1865, 
36% of all patients) were not treated with a glucose-lowering medication and thus did not fulfil the diagnos-
tic criteria of type 2 diabetes; (2) of the patients treated with one or more glucose-lowering medications (often 
including insulin and/or sulphonylureas), 20% had HbA1c-values below 42 mmol/mol (6%) and 1% had critically 
low HbA1c values <30 mmol/mol (<4.9%), indicating overtreatment. Conversely, 8% of all patients had Hba1c 
values >75 mmol/mol (>9%), indicating possible undertreatment.
A surprising finding was that based on HbA1c-value, 36% (n = 1,865) of all the admitted patients did meet 
the criteria for their diagnosis of type 2 diabetes. The diagnoses were all registered by a physician authorized in 
Denmark and could have been registered many years prior to the index admission. Thus, one potential explana-
tion for our finding could be that type 2 diabetes is not a chronic disease but rather a condition that may in some 
cases remit with old age – a notion that has been proposed before32,33. Hence, Abdelhafiz et al. proposed that 
frailty among older people with type 2 diabetes might lead to the remission of type 2 diabetes with the suggested 
mechanisms being weight loss accompanied by reduced amounts of visceral fat and thereby improved insulin 
sensitivity32. Such a mechanism bears resemblance to that described for patients having bariatric surgery and/or 
substantial weight loss and afterwards experience remission of their type 2 diabetes34,35.
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n (%)
Unique patients, number 5172 (100%)
Gender
Male 2392 (46%)
Female 2780 (54%)
Age in years (median, IQR) 84 (81.5–87.6)
Days of admission (median, IQR) 4 (1–9)
BMI (n = 4139)
<18.5 163 (4%)
18.5 – <25 1685 (41%)
25 – <30 1454 (35%)
30 – <40 766 (19%)
≥40 71 (2%)
Charlson Comorbidity Index
0 0 (0%)
1 342 (7%)
2 602 (12%)
>2 4228 (82%)
HbA1c (mmol/mol)
<30 57 (1%)
30–41 1304 (25%)
42–47 1214 (23%)
48–52 757 (15%)
53–57 544 (11%)
58–74 891 (17%)
≥75 405 (8%)
LDL (mmol/L) (n = 2983)
<1.8 1379 (46%)
1.8–2.5 856 (29%)
>2.5 748 (25%)
Total cholesterol (mmol/L) (n = 2222)
<5 1820 (82%)
≥ 5 402 (18%)
HDL (mmol/L) (n = 3105)
≤1 842 (27%)
>1 2263 (73%)
Creatinine (normal range men: 50–90, women: 
60–105) (µmol/L) (n = 5154)
Within range 2386 (46%)
Above range 2541 (49%)
Under range 227 (4%)
eGFR (mL/min/1,73m2) (n = 4221)
≤60 2426 (57%)
>60 1795 (43%)
Haemoglobin (normal range women: 7.3–9.5, men: 
8.3–10.5) (mmol/L) (n = 5118)
Within range 2191 (43%)
Above range 64 (1%)
Under range 2863 (56%)
TSH (normal range 0.35–4.0 or 0.65–4.80) (IU/L) (n = 3862)
Within range 3278 (85%)
Above range 295 (8%)
Under range 289 (7%)
Table 1. Patient characteristics for all patients with type 2 diabetes ≥80 years included in the study. Values are 
displayed in absolute numbers, percentages and median (inter-quartile range). For haemoglobin and creatinine, 
the reference values are displayed for men and women separately.
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We report that only 17% of included patients had an HbA1c between 58–75 mmol/mol (7.5–9%), the interval 
generally recommended for elderly with significant comorbidities and limited life expectancy. That our patients were 
indeed highly comorbid is evidenced by the Charlson comorbidity score, where 94% scored 2 or more36. Of those 
with an HbA1c <42 mmol/mol (<6.0%), 25% were treated with one or more glucose-lowering medications. These 
findings are in line with findings from other studies that have raised concerns about the potential overtreatment of 
older people with type 2 diabetes12,23,24,37–39. Among these is a large register-based study by Tseng et al. including 
652,738 patients from the Veteran Health Administration. They reported that approximately 50% of patients aged 
75 years or older, who were treated with insulin and/or sulphonylureas, had an HbA1c <53 mmol/mol (<7%)12. 
Similarly, results from The Fremantle Diabetes Cohort Study, which included 367 patients over the age of 75 with 
type 2 diabetes showed that approximately three of five (61%) of the patients had an HbA1c <53 mmol/mol (<7%)37. 
As treatment needs to be individualized according to a patient’s preferences and resources as well as life expectancy 
it is of interest that in our cohort dementia was registered as a diagnosis for 16% and non-skin malignancy for 19% of 
the included patients. Studies of frail patients with type 2 diabetes and limited life expectancy, such as nursing home 
residents, have suggested that particularly elderly with dementia are overtreated with glucose-lowering medications. 
Thus, in a nursing home population, 46–74% of the patients had an HbA1c <53 mmol/mol (<7%)24,39,40. Although 
the distributions of Hba1c-values in the mentioned nursing home studies were similar to ours, cognitive and func-
tional impairment may be more frequent in the nursing home setting. One percent (n = 70) of our population had 
hypoglycemia as the primary cause of admission. However, this is likely an underestimate of the number of patients 
at high risk of hypoglycemia. In older people, hypoglycemia can go undiscovered and be difficult to recognize due 
to unspecific symptoms11. Thus, the substantial proportion of patients, who in the context of near-normal Hba1c 
(i.e. below 42 mmol/mol (6%)) continued treatment with a sulphonylurea (n = 70) or insulin (n = 82) could be 
considered at high risk of hypoglycemic events11,16. Thus, our study adds to the evidence suggesting that the recom-
mendations favoring looser glycemic control in elderly, comorbid people similar to our population has not been fully 
adopted into clinical practice.
Our study has important strengths such as the large sample size, the high data quality from rather accu-
rate national registers with the possibility of linking biochemical data with health record data and drug use. 
Nonetheless, this register-based study also has some limitations. In our study, only 34% of elderly patients with a 
diagnosis of type 2 diabetes were treated with glucose-lowering medications. Other studies on glycemic control 
in older people, including the mentioned studies of nursing home residents and larger cohort studies report a 
much higher proportion of patients treated with glucose-lowering medication. Thus, between 85–100% of the 
patients received glucose-lowering medication in other cohort studies of a general population with type 2 dia-
betes12,23,37, and up to 86% were pharmacologically treated in studies investigating glycemic control in nursing 
home residents24,39,40. Our lower treatment prevalence is most likely due to the fact that many patients in our 
cohort did not meet the criteria for type 2 diabetes at the time of study. Since our study was based on a cohort 
identified by a hospital admission, and data analyses were limited to the time around hospital admission, we 
did not have information on the duration of diabetes or the glycemic control and use of antidiabetic medication 
over time. Access to this information could have strengthened our interpretation particularly the reason for the 
high proportion of patients not fulfilling the diagnostic criteria for type 2 diabetes. There is some indication that 
our cohort does not fully reflect the population in the capital region of Denmark. Thus, in our cohort, 54% were 
female, while the concurrent female proportion in the general population was 65%. The reason for such relative 
underrepresentation of females in our cohort is unclear. Another issue is that 56% had a hemoglobin below ref-
erence level, which theoretically could lead to an underestimation of the HbA1c-values. However, as proposed by 
samples from another Danish population, mild to moderate anemia does not seem have significant impact on the 
interpretation of HbA1c-values41.
Co-morbidities n (%)
Hypertension 3648 (71%)
Atrial fibrillation 1990 (38%)
Congestive heart failure 1650 (32%)
Cerebrovascular disease 1547 (30%)
Chronic pulmonary disease 1207 (23%)
Moderate to severe renal disease 1079 (21%)
Non-skin malignancy 984 (19%)
Peripheral vascular disease 930 (18%)
Dementia 831 (16%)
Myocardial infarction 689 (13%)
Thyroid disorders 524 (10%)
Depression 455 (9%)
Peptic ulcer disease 400 (8%)
Rheumatologic disease 137 (3%)
Metastatic solid tumor 124 (2%)
Moderate or severe liver disease 41 (1%)
Schizophrenia 10 (0%)
Table 2. Number of patients with co-morbidities, using all available data for each individual.
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In this hospital-based cohort consisting of more than 5000 patients, few patients ≥80 years with type 2 diabe-
tes had an HbA1c within the limits generally recommended for this population. Many patients were not treated 
with glucose-lowering medications and had HbA1c-values that could not justify a diagnosis of type 2 diabetes. Of 
Figure 1. Distribution of individual HbA1c-values for patients with type 2 diabetes >80 years with and without 
glucose-lowering medications divided into HbA1c-categories. HbA1c-values on the x-axis are displayed in both 
percentage and in mmol/mol. (a) Displays HbA1c-values for all patients (n = 5172). (b) Displays HbA1c-values 
for patients treated with glucose-lowering medications (n = 1758).
Number of glucose-
lowering medications
HbA1c
<30 30–41 42–47 48–52 53–57 58–74 75+ Total
0 42 (74%) 976 (75%) 847 (70%) 482 (64%) 326 (60%) 518 (58%) 223 (55%) 3414 (66%)
1 12 (21%) 279 (21%) 284 (23%) 217 (29%) 155 (29%) 250 (28%) 113 (28%) 1310 (25%)
2 2 (4%) 43 (3%) 75 (6%) 50 (7%) 55 (10%) 103 (12%) 60 (15%) 388 (8%)
3 0 (0%) 5 (0%) 8 (1%) 7 (1%) 7 (1%) 19 (2%) 8 (2%) 54 (1%)
4 1 (2%) 1 (0%) 0 (0%) 1 (0%) 0 (0%) 2 (0%) 1 (0%) 6 (0%)
Total 57 (100%) 1304 (100%) 1214 (100%) 757 (100%) 543 (100%) 892 (100%) 405 (100%) 5172 (100%)
Table 3. Number of patients grouped by number of glucose-lowering medications administered at the time of 
hospital discharge and HbA1c-value (obtained ±90 days before hospital admission). HbA1c-values are divided 
into categories and displayed in mmol/mol.
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those treated with one or more glucose-lowering medications, quite many had either high or low HbA1c-values, 
suggesting under- and overtreatment, respectively. Our study supports the assumption that a diagnosis of type 2 
diabetes may remit with age. Moreover, it suggests that recommendations for glycemic control in elderly patients 
with type 2 diabetes are not fully implemented in clinical practice.
Methods
Study cohort and data sources. The study was a retrospective cohort study using data from the Capital 
Region of Denmark from January 1, 2012 to May 15, 2016. We analyzed the first hospital admission for each 
patient, where an HbA1c measurement in proximity to the hospital admission (±90 days) was available. On 
admission, patients were required to be at least 80 years of age and have a prior diagnosis of type 2 diabetes (ICD-
10 code DE11). Diagnoses were obtained from the regional system feeding data to The Danish National Patient 
Register42. Drug utilization was obtained from The Electronic Patient Medication module, which is a database 
for in-hospital drug-use in the Capital Region of Denmark43. HbA1c-values, as well as biochemical status (blood 
lipids (cholesterol, LDL and HDL), kidney function (creatinine, eGFR), hemoglobin levels and TSH), were gath-
ered from The Clinical Laboratory Information System44. Body Mass Index (BMI) was obtained from the medical 
health records. Data sources were linked using the unique and permanent Danish identification number45.
Exposure and comorbidity. Exposure to a glucose-lowering medication was defined as an active prescrip-
tion of a glucose-lowering medication (Anatomical Therapeutic Chemical classification (ATC)-code A10) at the 
time of discharge from the hospital and with at least one administration during the hospital admission. To evalu-
ate patient comorbidity, we used diagnoses to calculate The Charlson Comorbidity Index, which is a measure of 
comorbidity burden and has been shown to be correlated with life expectancy36.
Statistical methods. Data are presented using standard descriptive statistics including median and inter-
quartile ranges. Data management was conducted using R46.
ethics. According to the Danish “Act on Research Ethics Review of Health Research Projects” section 14 (2), 
retrospective register-based studies do not require ethical approval in Denmark. The study was approved by The 
Danish Data Protection Agency (BFH-2016–058, I-Suite nr.: 04906) and The Danish Patient Safety Authority 
(3-3013-1884/1/).
compliance with ethics guidelines. This article is based on previously conducted health data and does 
not contain any studies with human participants or animals performed by any of the authors.
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